We are live on ! Find out more
KNSA icon

Kiniksa Pharmaceuticals
KNSA

103 hedge funds and large institutions have $346M invested in Kiniksa Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 41 increasing their positions, 27 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 27

31% more call options, than puts

Call options by funds: $3.67M | Put options by funds: $2.79M

10% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 20

2% more funds holding

Funds holding: 101 → 103 (+2)

5% more capital invested

Capital invested by funds: $330M → $346M (+$15.8M)

2.46% less ownership

Funds ownership: 89.31% → 86.85% (-2.5%)

Holders
103
Holders Change
+2
Holders Change %
+1.98%
% of All Funds
1.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
41
Reduced
27
Closed
20
Calls
$3.67M
Puts
$2.79M
Net Calls
+$874K
Net Calls Change
+$1.26M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$4.47M
2
Renaissance Technologies
Renaissance Technologies
New York
+$3.73M
3
Millennium Management
Millennium Management
New York
+$3.69M
4
ECM
Endurant Capital Management
California
+$3M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.8M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$6.99M
2
LPC
Lion Point Capital
New York
-$5.42M
3
OM
Opaleye Management
Massachusetts
-$3.5M
4
BC
Boxer Capital
California
-$3.31M
5
WP
Woodline Partners
California
-$2.67M
Name Holding Trade Value Shares
Change 		Change in
Stake
PPA
26
Parametric Portfolio Associates
Washington
$1.76M +$978K +79,609 +113%
IHAM
27
Integral Health Asset Management
New York
$1.65M +$1.72M +140,000 New
Bank of New York Mellon
28
Bank of New York Mellon
New York
$1.58M -$13.4K -1,091 -0.8%
Bank of America
29
Bank of America
North Carolina
$1.55M +$1.12M +91,030 +224%
Susquehanna International Group
30
Susquehanna International Group
Pennsylvania
$1.38M -$119K -9,650 -8%
PHP
31
Parkman Healthcare Partners
Connecticut
$1.34M +$1.4M +113,644 New
N
32
Nuveen
North Carolina
$1.26M +$55.2K +4,493 +4%
Rafferty Asset Management
33
Rafferty Asset Management
New York
$1.04M +$22.4K +1,819 +2%
Walleye Capital
34
Walleye Capital
New York
$981K +$1.02M +83,364 New
Deutsche Bank
35
Deutsche Bank
Germany
$946K +$15.4K +1,255 +2%
JCIA
36
Jackson Creek Investment Advisors
Colorado
$907K +$947K +77,069 New
UBS Group
37
UBS Group
Switzerland
$900K -$77K -6,262 -8%
Charles Schwab
38
Charles Schwab
California
$900K +$28.1K +2,286 +3%
Citigroup
39
Citigroup
New York
$869K +$180K +14,656 +25%
HWAM
40
Hennion & Walsh Asset Management
New Jersey
$823K +$53.7K +4,368 +7%
Marshall Wace
41
Marshall Wace
United Kingdom
$821K +$857K +69,723 New
Citadel Advisors
42
Citadel Advisors
Florida
$798K +$518K +42,150 +164%
Los Angeles Capital Management
43
Los Angeles Capital Management
California
$706K +$343K +27,886 +87%
BNP Paribas Financial Markets
44
BNP Paribas Financial Markets
France
$670K +$630K +51,275 +910%
Barclays
45
Barclays
United Kingdom
$653K -$258K -21,026 -27%
LPC
46
Lion Point Capital
New York
$647K -$5.42M -440,748 -89%
CSS
47
Cubist Systematic Strategies
Connecticut
$635K +$167K +13,554 +34%
Ensign Peak Advisors
48
Ensign Peak Advisors
Utah
$621K -$259K -21,073 -29%
Swiss National Bank
49
Swiss National Bank
Switzerland
$621K – – –
PCM
50
Pinz Capital Management
New York
$471K +$492K +40,000 New
1
2
3 4 5

KNSA Hedge Fund Activity: Q4 2021 in Review

103 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q4 2021, worth a combined $346M — up 4.8% from $330M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new KNSA positions and 20 closed out — a net gain of 2 holders — while 41 added to existing stakes and 27 trimmed.

The largest buyer was BlackRock, adding an estimated $4.47M. The largest seller was State Street, cutting an estimated $6.99M.

  • 103 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q4 2021, up from 101 in Q3 2021.
  • Funds reported $346M of Kiniksa Pharmaceuticals stock for Q4 2021, up 4.8% quarter-over-quarter.
  • 22 funds opened new Kiniksa Pharmaceuticals positions in Q4 2021 and 20 closed out, a net change of +2 holders.
  • The largest Kiniksa Pharmaceuticals buyer in Q4 2021 was BlackRock, an estimated $4.47M added.
  • The largest Kiniksa Pharmaceuticals seller in Q4 2021 was State Street, an estimated $6.99M sold.

Based on aggregated 13F filings for Q4 2021.